Molecular Health and Collaborators Develop New Real-World Data Approach to Adverse Drug Reactions

Adverse drug reactions are often unpredictable and difficult to understand at the molecular level. In 3 recently published articles, researchers from Molecular Health and collaborators from the University of Florida, thinkQ², and Takeda Oncology demonstrate their new real-world data (RWD) approach to tackle this problem. In the first paper, authors lay out the underlying principles that they then applied in the latter 2 proof of concept studies.

According to Molecular Health, “By mapping population-level adverse drug reaction data extracted from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System back to molecular pathways and target profile data, the two proof-of-concept studies examined potential causes of cardiotoxicity and of colitis associated with well-known targeted cancer therapies. Using this analytical method, the authors developed hypotheses about different molecular mechanisms that accentuate or attenuate adverse effects depending on the nature of drug-drug combinations or on a drug’s target.”

Click here to read more.

(Source: Molecular Health, March 10^th, 2022)